Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 41.1914
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 684805601520.0
- FreeCF/Share 0.5421
- PFCF 1405.5944
- PE 58.4684
- Debt/Assets 0.4309
- DivYield 0.0078
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Published: May 06, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to treat breast cancer.
Read More
LLY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Eli Lilly and Company investment
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws. On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance.
Read More
Lilly declares second-quarter 2025 dividend
Published: May 05, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
An Investigation Has Commenced on Behalf of Eli Lilly and Company Shareholders. Contact Levi & Korsinsky to Discuss your LLY Losses
Published: May 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws. On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance.
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why.
Published: May 02, 2025 by: Barrons
Sentiment: Positive
Analysts were rushing to reiterate their conviction in the stock following Thursday's blow to Zepbound and Lilly shares.
Read More
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Anne White - President of Lilly Neuroscience Ilya Yuffa - President of Lilly International Jake Van Naarden - President of Lilly Oncology Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference …
Read More
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
Read More
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.
Read More
Why Eli Lilly Stock Is Sinking Today
Published: May 01, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Eli Lilly (LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m.
Read More
Initial Claims More Than Expectations
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Initial Claims More Than Expectations.
Read More
Eli Lilly CEO David Ricks on pricing of the new weight loss pill if approved
Published: May 01, 2025 by: CNBC Television
Sentiment: Neutral
Eli Lilly chairman and CEO David Ricks discusses the status of the company's weight loss drug pill.
Read More
Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Last week, 241K Americans filed for unemployment on Initial Jobless Claims, with Continuing Claims touching 1.9 million.
Read More
Here's What Key Metrics Tell Us About Lilly (LLY) Q1 Earnings
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
QCOM Earnings Sell-Off, CVS Turnaround Continues, LLY Disappoints
Published: May 01, 2025 by: Schwab Network
Sentiment: Neutral
While Microsoft (MSFT) and Meta Platforms (META) shined in the Big Tech space, Diane King Hall turns to a mixed earnings picture elsewhere on Wall Street. CVS Health (CVS) posted an earnings beat, raised guidance, and announced a Wegovy deal with Novo Nordisk (NVO), all contributing to its rally.
Read More
Eli Lilly shares slide despite weight-loss drug boost as company trims 2025 profit outlook
Published: May 01, 2025 by: Proactive Investors
Sentiment: Negative
Eli Lilly and Co (NYSE:LLY) shares fell as much as 7.7% at the open on Thursday after the drugmaker cut its 2025 profit forecast, overshadowing booming sales of its blockbuster weight-loss drugs. The pharmaceutical giant reported a 45% year-over-year jump in first-quarter revenue to $12.73 billion, slightly above Wall Street expectations, driven by surging demand for its GLP-1 drugs Mounjaro and Zepbound.
Read More
Eli Lilly CEO David Ricks on tariffs: We favor carrots, not sticks
Published: May 01, 2025 by: CNBC Television
Sentiment: Neutral
Eli Lilly chairman and CEO David Ricks discusses the potential impact of tariffs.
Read More
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
Published: May 01, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly CEO Dave Ricks said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The Trump administration has opened an investigation into how importing certain pharmaceuticals into the U.S. affects national security – a move widely seen as a prelude to initiating tariffs on drugs.
Read More
Eli Lilly (LLY) Q1 Earnings Lag Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago.
Read More
Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds
Published: May 01, 2025 by: WSJ
Sentiment: Positive
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
Read More
Eli Lilly Stock Slips as Lowered Profit Outlook Outweighs Solid Q1 Results
Published: May 01, 2025 by: Investopedia
Sentiment: Negative
Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.
Read More
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral GLP-1 agonist) in Type 2 diabetes in the first of seven obesity and diabetes Phase 3 trials.
Read More
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Published: May 01, 2025 by: Benzinga
Sentiment: Neutral
Eli Lilly and Company LLY will release earnings results for the first quarter, before the opening bell on Thursday, May 1.
Read More
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
Calls of the Day: Eli Lilly
Published: April 28, 2025 by: CNBC Television
Sentiment: Neutral
Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!
Read More
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Read More
Eli Lilly Stock Just Got Its First Bear. Where Weight-Loss Drugs Go From Here.
Published: April 28, 2025 by: Barrons
Sentiment: Negative
HSBC double downgraded Eli Lilly to Reduce, citing too much optimism around its new weight-loss pill, and the strength of Novo Nordisk's Ozempic brand.
Read More
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO Mr. David A. Ricks
- Employees 47000